Exercise testing: The catecholaminergic polymorphic ventricular tachycardia crystal ball?

Europace

Volumn 14, Issue 9, 2012, Pages 1225-1227

  Sy, Raymond W ^a,b   Krahn, Andrew D ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; EDITORIAL; EXERCISE; GENE MUTATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; PREDICTION; PRIORITY JOURNAL;

EXERCISE TEST; FEMALE; HUMANS; MALE; MUTATION; TACHYCARDIA, VENTRICULAR;

EID: 84865747546     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eus146     Document Type: Editorial

References (19)

1. Coumel P, Fidelle J, Lucet V, Attuel P, Bouvrain Y. Catecholamine-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: report of four cases. Br Heart J 1978;40(Suppl.):28-37.
2. Katz G, Arad M, Eldar M. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond. Curr Probl Cardiol 2009;34:9-43.
3. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995;91:1512-9.
4. Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 2001;103:485-90.
5. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002;106:69-74.
6. di Barletta MR, Viatchenko-Karpinski S, Nori A, Memmi M, Terentyev D, Turcato F et al. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation 2006;114:1012-9.
7. Lahat H, Eldar M, Levy-Nissenbaum E, Bahan T, Friedman E, Khoury A et al. Autosomal recessive catecholamine-or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation 2001;103:2822-7.
8. Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 2009;119:2426-34.
9. Sy RW, Gollob MH, Klein GJ, Yee R, Skanes AC, Gula LJ et al. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2011;8:864-71.
10. van der Werf C, Zwinderman AH, Wilde AA. Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments. Europace 2012;14:175-83.
11. Swan H, Laitinen P, Kontula K, Toivonen L. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol 2005;16:162-6.
12. van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 2011;57:2244-54.
13. Rosso R, Kalman JM, Rogowski O, Diamant S, Birger A, Biner S et al. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2007;4:1149-54.
14. Wilde AA, Bhuiyan ZA, Crotti L, Facchini M, De Ferrari GM, Paul T et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med 2008;358:2024-9.
15. Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 2003;89:66-70.
16. Hayashi M, Denjoy I, Hayashi M, Extramiana F, Maltret A, Roux-Buisson N et al. The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands. Europace 2012;14:1344-51.
17. Haugaa KH, Leren IS, Berge KE, Bathen J, Loennechen JP, Anfinsen OG et al. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening. Europace 2010;12:417-23.
18. Bauce B, Rampazzo A, Basso C, Bagattin A, Daliento L, Tiso N et al. Screening for ryanodine receptor type 2 mutations in families with effort-induced polymorphic ventricular arrhythmias and sudden death: early diagnosis of asymptomatic carriers. J Am Coll Cardiol 2002;40:341-9.
19. Krahn AD, Healey JS, Chauhan V, Birnie DH, Simpson CS, Champagne J et al. Systematic assessment of patients with unexplained cardiac arrest: Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER). Circulation 2009; 120:278-85.